Bristol-Myers Squibb

Asco-GU – Bristol’s renal cancer lead looks to be short-lived
EP Vantage
Mon, 02/11/19 - 08:24 pm
renal cell carcinoma
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
clinical trials
Sutent
Forget Bristol-Myers: Regeneron takes on Merck for the heavyweight title in non-small cell lung cancer
Endpoints
Fri, 02/8/19 - 11:40 am
Regeneron
Merck
Bristol-Myers Squibb
PD-1/L1 therapy
Libtayo
Keytruda
Opdivo
non-small cell lung cancer
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Wed, 02/6/19 - 10:28 pm
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Powerful Senate committee invites pharma executives to testify
Reuters
Tue, 02/5/19 - 11:31 pm
Senate
drug pricing
AbbVie
AstraZeneca
Bristol-Myers Squibb
JNJ
Merck
Pfizer
Sanofi
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Mon, 02/4/19 - 11:47 am
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Fierce Pharma
Fri, 02/1/19 - 10:47 pm
M&A
Bristol-Myers Squibb
Celgene
Report: five companies would take brunt of Trump Part B proposal
BioCentury
Fri, 02/1/19 - 11:24 am
Donald Trump
Medicare Part B
Amgen
Regeneron
Bristol-Myers Squibb
Genentech
Roche
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Fierce Pharma
Fri, 02/1/19 - 12:18 am
M&A
Celgene
Bristol-Myers Squibb
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Motley Fool
Sun, 01/27/19 - 12:03 pm
Bristol-Myers Squibb
earnings
M&A
Celgene
BMS talks up Celgene merger to divert Opdivo disappointment
Fierce Pharma
Fri, 01/25/19 - 12:08 am
Bristol-Myers Squibb
Celgene
Opdivo
Yervoy
Good latest quarter from BMS
GoinPharma
Fri, 01/25/19 - 12:06 am
Bristol-Myers Squibb
earnings
In Another Lung Cancer Setback, Bristol Yanks FDA App For Drug Combo
Xconomy
Thu, 01/24/19 - 10:57 am
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
FDA
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
Tue, 01/22/19 - 11:55 pm
M&A
Celgene
Bristol-Myers Squibb
Eli Lilly
Loxo Oncology
Is the Smoldering NASH Market Ready to Burst Into Flames?
BioSpace
Tue, 01/22/19 - 11:52 am
NASH
Allergan
Regeneron
Alnylam
AstraZeneca
Merck
Takeda
Gilead Sciences
Bristol-Myers Squibb
Intercept Pharmaceuticals
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Stat
Tue, 01/22/19 - 11:38 am
Celgene
drug pricing
M&A
Bristol-Myers Squibb
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
Sat, 01/19/19 - 06:35 pm
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
Wed, 01/16/19 - 11:53 am
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices
Fierce Pharma
Tue, 01/15/19 - 11:25 am
US Congress
M&A
Bristol-Myers Squibb
Celgene
drug pricing
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Opdivo meets OS endpoint in esophageal cancer trial
BioCentury
Wed, 01/9/19 - 07:24 pm
Ono Pharmaceutical
Opdivo
esophageal cancer
Bristol-Myers Squibb

Pages